# Topical SGX302 for Mild-to-Moderate Psoriasis

> **NCT05442190** · PHASE2 · COMPLETED · sponsor: **Soligenix** · enrollment: 15 (actual)

## Conditions studied

- Psoriasis
- Plaque Psoriasis
- Psoriasis Vulgaris

## Interventions

- **DRUG:** Hypericin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05442190
- **Lead sponsor:** Soligenix
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-14
- **Primary completion:** 2025-10-22
- **Final completion:** 2025-11-17
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2026-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05442190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05442190, "Topical SGX302 for Mild-to-Moderate Psoriasis". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT05442190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*